Bio-Rad Laboratories (BIO) Q4 2024 earnings summary

Executive summary

• Achieved revised 2024 guidance for revenue and operating margin, with Clinical Diagnostics growth offsetting Life Science segment declines amid biopharma market softness and improved gross margins from cost management initiatives.

• Entered a binding offer to acquire Stilla Technologies, expected to close by end of Q3 2025, to enhance digital PCR portfolio and support diverse research and clinical applications.

• Implemented a 5% workforce reduction and other cost management initiatives to drive sustained margin improvements.

• Innovation focus includes new product launches and portfolio refreshes in digital PCR and process chromatography.

Financial highlights

• Q4 2024 net sales were $668M, down 2% year-over-year; full year 2024 net sales were $2,567M, down 3.9%.

• Q4 non-GAAP net income was $81M ($2.90 EPS); full year non-GAAP gross margin reached 55% (vs. 54.2% in 2023).

• Q4 operating income was $58M (8.7% margin); full year non-GAAP operating margin was 12.9% (vs. 14.2% in 2023).

• Q4 reported net loss of $716M due to a $977M loss from equity security holdings (Sartorius AG shares); full-year GAAP net loss was $1,844M.

• Free cash flow for 2024 was $290M, up from $218M in 2023.

Outlook and guidance

• 2025 currency-neutral revenue growth expected between 1.5%-3.5%, excluding acquisitions; non-GAAP operating margin forecasted at 13%-13.5%.

• Q1 2025 revenue expected to be down 5-7% year-over-year, with sequential improvement through the year.

• Life Science group revenue growth guided at 1.5%-3.5%; process chromatography to grow high single digits.

• Diagnostics group revenue growth guided at 2%-3%, with headwinds from donor screening exit and China reimbursement.

• Free cash flow for 2025 targeted at $310M-$330M.